Search Results - "Pallis, A."

The relationship between port choice and terminal involvement of alliance members in container shipping by Notteboom, Theo E., Parola, Francesco, Satta, Giovanni, Pallis, Athanasios A.

“…This paper examines in which ways the changing organizational routines of shipping (i.e., alliance formation and vertical integration in container terminal…”
Get full text

Management of elderly patients with NSCLC; updated expert's opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology by Pallis, A.G., Gridelli, C., Wedding, U., Faivre-Finn, C., Veronesi, G., Jaklitsch, M., Luciani, A., O'Brien, M.

“…Non-small-cell lung cancer (NSCLC) is a very common disease in the elderly population and its incidence in this particular population is expected to increase…”
Get full text

Container terminal automation: assessment of drivers and benefits by Knatz, Geraldine, Notteboom, Theo, Pallis, Athanasios A.

“…This study identifies and analyzes the relative importance of the multi-faceted factors that drive the decision to automate container terminals and the…”
Get full text

EORTC workshop on clinical trial methodology in older individuals with a diagnosis of solid tumors by Pallis, A.G., Ring, A., Fortpied, C., Penninckx, B., Van Nes, M.C., Wedding, U., vonMinckwitz, G., Johnson, C.D., Wyld, L., Timmer-Bonte, A., Bonnetain, F., Repetto, L., Aapro, M., Luciani, A., Wildiers, H.

“…Due to the aging of the population, the number of older patients diagnosed with a malignant disease is increasing. A multidisciplinary approach to the senior…”
Get full text

A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer by Pallis, A.G., Boukovinas, I., Ardavanis, A., Varthalitis, I., Malamos, N., Georgoulias, V., Mavroudis, D.

“…The Breast Cancer Study Group of the Hellenic Oncology Research Group conducted a phase III trial of single-agent capecitabine versus the…”
Get full text

Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC by Pallis, A.G, Syrigos, K.N

“…Abstract Improvements in our understanding of the molecular biology of cancer have shifted management of lung cancer toward molecular-guided, individualized…”
Get full text

Questionnaires and instruments for a multidimensional assessment of the older cancer patient: What clinicians need to know? by Pallis, A.G, Wedding, U, Lacombe, D, Soubeyran, P, Wildiers, H

“…Abstract Due to the ageing of the population in the Western world, a significant increase in the number of older patients diagnosed with neoplastic diseases is…”
Get full text

Private entry in cruise terminal operations in the Mediterranean Sea by Pallis, Athanasios A., Parola, Francesco, Satta, Giovanni, Notteboom, Theo E.

“…This study examines private entry strategies and internationalization patterns in the cruise terminal industry. The focus is on the second biggest cruise…”
Get full text

International validation of the EORTC QLQ-ELD14 questionnaire for assessment of health-related quality of life elderly patients with cancer by Wheelwright, S, Darlington, A-S, Fitzsimmons, D, Fayers, P, Arraras, J I, Bonnetain, F, Brain, E, Bredart, A, Chie, W-C, Giesinger, J, Hammerlid, E, O'Connor, S J, Oerlemans, S, Pallis, A, Reed, M, Singhal, N, Vassiliou, V, Young, T, Johnson, C

“…Background: Older people represent the majority of cancer patients but their specific needs are often ignored in the development of health-related quality of…”
Get full text

Targeted therapies in the treatment of advanced/metastatic NSCLC by Pallis, A.G, Serfass, L, Dziadziuszko, R, van Meerbeeck, J.P, Fennell, D, Lacombe, D, Welch, J, Gridelli, C

“…Abstract The treatment of advanced non-small cell lung cancer (NSCLC) has evolved substantially during the last years. Chemotherapy remains the cornerstone of…”
Get full text

EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts’ opinion for the treatment of non-small-cell lung cancer in an elderly population by Pallis, A.G., Gridelli, C., van Meerbeeck, J.P., Greillier, L., Wedding, U., Lacombe, D., Welch, J., Belani, C.P., Aapro, M.

“…Non-small-cell lung cancer (NSCLC) represents a common health issue in the elderly population. Nevertheless, the paucity of large, well-conducted prospective…”
Get full text

EORTC elderly task force position paper: Approach to the older cancer patient by Pallis, A.G, Fortpied, C, Wedding, U, Van Nes, M.C, Penninckx, B, Ring, A, Lacombe, D, Monfardini, S, Scalliet, P, Wildiers, H

“…Abstract As a result of an increasing life expectancy, the incidence of cancer cases diagnosed in the older population is rising. Indeed, cancer incidence is…”
Get full text

Biomarkers of clinical benefit for anti-epidermal growth factor receptor agents in patients with non-small-cell lung cancer by Pallis, A G, Fennell, D A, Szutowicz, E, Leighl, N B, Greillier, L, Dziadziuszko, R

“…Non-small-cell lung cancer (NSCLC) remains by far the major cause of cancer-related death in the Western world in both men and women. The majority of patients…”
Get full text

Are we treating enough elderly patients with early stage non-small cell lung cancer? by Pallis, A.G, Scarci, M

“…Abstract Despite the fact that non-small-cell lung cancer (NSCLC) is very common in the older population, these patients are frequently underrepresented in…”
Get full text

A phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with estrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer by Campone, M., Bachelot, T., Penault-Llorca, F., Pallis, A., Agrapart, V., Pierrat, M. J., Poirot, C., Dubois, F., Xuereb, L., Bossard, C. J., Guigal-Stephan, N., Lockhart, B., Andre, F.

“…Purpose The primary objective of this multicentric dose allocation and dose expansion study was to determine the MTD and the DLTs of the lucitanib (a tyrosine…”
Get full text

Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small-cell lung cancer: clinical and molecular considerations by Pallis, A, Briasoulis, E, Linardou, H, Papadimitriou, C, Bafaloukos, D, Kosmidis, P, Murray, S

“…Non-Small-Cell Lung Cancer (NSCLC) with somatic mutations of the epidermal growth factor receptor (EGFR) is anticipated to respond to small-molecule tyrosine…”
Get more information

Transparency in port governance: Setting a research agenda by Brooks, Mary R, Knatz, Geraldine, Pallis, Athanasios A, Wilmsmeier, Gordon

“…This study examines the concept of transparency as practiced (or not) in ports. It explores the availability of information to the general public and port…”
Get full text

Clinical relevance of circulating CK-19mRNA-positive tumour cells before front-line treatment in patients with metastatic breast cancer by Androulakis, N, Agelaki, S, Perraki, M, Apostolaki, S, Bozionelou, V, Pallis, A, Kalbakis, K, Xyrafas, A, Mavroudis, D, Georgoulias, V

“…Background: To investigate the clinical relevance of CK-19mRNA-positive circulating tumour cells (CTCs) detected before the initiation of front-line treatment…”
Get full text

Efficacy and treatment tolerance in older patients with NSCLC: a meta-analysis of five phase III randomized trials conducted by the Hellenic Oncology Research Group by Pallis, A.G., Karampeazis, A., Vamvakas, L., Vardakis, N., Kotsakis, A., Bozionelou, V., Kalykaki, A., Hatzidaki, D., Mavroudis, D., Georgoulias, V.

“…Approximately 50% of newly diagnosed cases of non-small-cell lung cancer (NSCLC) are observed in patients >65 years, while 30%–40% of cases occur in patients…”
Get full text

'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer by PALLISL, A. G, VOUTSINA, A, CEORGOULIAS, V, KALIKAKI, A, SOUGLAKOS, J, BRIASOULIS, E, MURRAY, S, KOUTSOPOULOS, A, TRIPAKI, M, STATHOPOULOS, E, MAVROUDIS, D

“…'Classical' mutations in the EGFR tyrosine kinase domain (exons 18, 19 and 21) have been associated with sensitivity to tyrosine kinase inhibitors (TKIs) in…”
Get full text